Vifor Pharma AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Vifor Pharma AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH185425D
  • |
  • Pages: 43
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Vifor Pharma AG (Vifor Pharma), a subsidiary of Galenica Ltd is a healthcare service provider that discovers, develops, manufactures, and commercializes prescription and over the counter pharmaceutical products for the treatment of iron replacement therapy. The company offers products for treatment of iron deficiency, a range of non prescription products for the treatment of infectious diseases, and iron based phosphate binder for controlling serum phosphorus levels in patients with chronic kidney disease undergoing dialysis. Vifor Pharma's clinical programs concentrates on safety and efficacy of Broncho Vaxom for respiratory tract infections in children and in chronic obstructive pulmonary disease in adults; and uro vaxom for recurrent urinary tract infections. It has manufacturing facilities in Switzerland, the UK and Portugal. Vifor Pharma is headquartered in Glattbrugg, Switzerland.

Vifor Pharma AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Relypsa Secures USD2.6 Million in Venture Funding 12

Relypsa Raises US$80 Million In Series C Financing 13

Relypsa Secures USD62.4 Million in Venture Funding 14

Partnerships 15

Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 15

Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 15

Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 16

Probi Enters Into Co-Marketing Agreement With Vifor Pharma 17

Licensing Agreements 18

Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 18

Vifor Pharma Expands Licensing Agreement with ChemoCentryx 19

Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 20

Vifor Pharma Enters into Licensing Agreement with ChemoCentryx for CCX168 21

Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 22

Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 23

Vifor Pharma Enters into Licensing Agreement with Bitop for Ectoin Allergy Eye Drops and Ectoin Allergy Nasal Sprays 24

Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 25

Hikma Pharma Enters Into Licensing Agreement With Vifor Pharma For Ferinject 26

Equity Offering 27

Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 27

Relypsa Raises USD172 Million in Public Offering of Shares 28

Relypsa Completes Public Offering Of Shares For US$101.2 Million 29

Relypsa Completes IPO For US$86.7 Million 31

Acquisition 32

Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 32

Relypsa May Sell Itself 34

Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 34

Vifor Pharma AG-Key Competitors 36

Key Employees 37

Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 40

Corporate Communications 40

Oct 06, 2016: Galenica: New Management at Vifor Pharma and new Galenica Group CFO designated 40

May 10, 2016: Vifor Pharma appoints Colin Bond as Chief Financial Officer 41

Government and Public Interest 42

Feb 20, 2017: Vifor Pharma and ECCO Announces One-Year Research Grant for Iron Deficiency 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43

List of Figures

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Vifor Pharma AG, Pharmaceuticals & Healthcare, Key Facts 1

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Vifor Pharma AG, Deals By Therapy Area, 2011 to YTD 2017 9

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Relypsa Secures USD2.6 Million in Venture Funding 12

Relypsa Raises US$80 Million In Series C Financing 13

Relypsa Secures USD62.4 Million in Venture Funding 14

Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 15

Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 15

Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 16

Probi Enters Into Co-Marketing Agreement With Vifor Pharma 17

Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 18

Vifor Pharma Expands Licensing Agreement with ChemoCentryx 19

Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 20

Vifor Pharma Enters into Licensing Agreement with ChemoCentryx for CCX168 21

Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 22

Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 23

Vifor Pharma Enters into Licensing Agreement with Bitop for Ectoin Allergy Eye Drops and Ectoin Allergy Nasal Sprays 24

Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 25

Hikma Pharma Enters Into Licensing Agreement With Vifor Pharma For Ferinject 26

Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 27

Relypsa Raises USD172 Million in Public Offering of Shares 28

Relypsa Completes Public Offering Of Shares For US$101.2 Million 29

Relypsa Completes IPO For US$86.7 Million 31

Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 32

Relypsa May Sell Itself 34

Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 34

Vifor Pharma AG, Key Competitors 36

Vifor Pharma AG, Key Employees 37

Vifor Pharma AG, Other Locations 38

Vifor Pharma AG, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Vifor Pharma AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16263
Site License
USD 500 INR 32525
Corporate User License
USD 750 INR 48788

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com